CDx success insights from Xalkori and Zelboraf

JoshLowth

Junior Member

Join Date: Apr 2012

Posts: 4
- Share
- Tweet
#1

CDx success insights from Xalkori and Zelboraf

04-24-2012, 12:15 AM

4th Molecular Diagnostics for Cancer Drug Development
Meet the oncology and diagnostics experts you need to deliver better, safer drugs to market quicker
25 - 28 June 2012, Boston
www.moleculardiagnostics-cancer.com

Featuring 31 expert speakers, including:

Dr Richard Buller, Vice President, Translational Oncology, Pfizer

Dr Miu Chau, Global Head, Companion Diagnostics Operations, Genentech

Dr Mitch Raponi, Senior Director, Molecular Diagnostics & Translational Medicine, Clovis Oncology

This meeting will profile those at the cutting edge of personalized medicine in oncology to give you a thorough review of best practice in end to end drug and diagnostic development from discovery to commercialization.

For more information please visit the website: www.moleculardiagnostics-cancer.com or get in touch on [email protected].

Josh Lowth
Hanson Wade
Tags: companion diagnostics, molecular diagnostics, oncology, personalized medicine

Previous template Next

Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems

by mylaser

Kheloyaar: The Complete Guide to Kheloyaar Loginand Kheloyaar ID
The online gaming industry has transformed the way people enjoy digital entertainment. As technology continues to improve, players are looking for platforms that offer convenience, security, and a seamless user experience. Kheloyaarhas gained attention among users who value an easy-to-use platform, quick account access, and a simple registration process.
Whether you're exploring Kheloyaar for the first time or want to understand...
- Channel: Articles
Today, 09:27 PM
Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems

by SEQadmin2

Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...
- Channel: Articles
Today, 11:10 AM
Cancer Drug Resistance: The Lingering Barrier to Rising Survival

by SEQadmin2

Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
- Channel: Articles
Yesterday, 05:17 AM

Topics	Statistics	Last Post
New Analysis Splits Leukemia Into 16 Epigenomic Subgroups by SEQadmin2 Started by SEQadmin2, Today, 10:04 AM	0 responses 8 views 0 reactions	Last Post by SEQadmin2 Today, 10:04 AM
Genome-Wide CRISPR Screen Uncovers Unlikely Psoriasis Target by SEQadmin2 Started by SEQadmin2, Yesterday, 10:08 AM	0 responses 7 views 0 reactions	Last Post by SEQadmin2 Yesterday, 10:08 AM
Engineered Protein Motor Takes Its First Steps Along DNA Track by SEQadmin2 Started by SEQadmin2, 07-07-2026, 11:05 AM	0 responses 10 views 0 reactions	Last Post by SEQadmin2 07-07-2026, 11:05 AM
High-Resolution Sequencing Exposes Hidden Toxoplasma Diversity by SEQadmin2 Started by SEQadmin2, 07-02-2026, 11:08 AM	0 responses 31 views 0 reactions	Last Post by SEQadmin2 07-02-2026, 11:08 AM

Unconfigured Ad

CDx success insights from Xalkori and Zelboraf

Latest Articles

ad_right_rmr

News